Drug profile · INN
ofloxacin
OCUFLOX
ofloxacin (OCUFLOX) is a bacterial dna gyrase inhibitor. Associated with AbbVie. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — ofloxacin
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 2
- Programs
- 25
- Data quality
- 0.89
Quick answer
ofloxacin (OCUFLOX) is a bacterial dna gyrase inhibitor. Associated with AbbVie. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial DNA gyrase inhibitor
Primary target: Bacterial DNA gyrase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is ofloxacin?
ofloxacin (OCUFLOX) is a bacterial dna gyrase inhibitor. Associated with AbbVie. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for ofloxacin?
OCUFLOX is a marketed brand name for ofloxacin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ofloxacin?
ofloxacin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.